Announced Tue, 15 Sept, 2026 · 10:27 IST
Neuland commissions first peptide manufacturing module; expansion ahead of schedule
NEULANDLAB · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Price reaction · full curve 14 horizons · vs prior close
-3.7%1-day move
₹23455.00
prior close
₹23120.00
base price
In-mkt
timing
5m10m15m30m1D2D3D4D5D7D15D1M2M3M
+0.4-0.7-0.6-0.6-3.7-3.6-3.2-3.3-3.8-6.5-7.8———
Up moveDown movePending
AI summary
Neuland Labs has begun operations at the first of four planned peptide manufacturing modules, backed by a 30 million dollar investment. Module 1 offers 7000L total reactor capacity, with Module 2 (up to 18,000L) already being built ahead of the original timeline. The company is expanding beyond obesity drugs into oncology peptides. Quarterly revenues rose 116 percent, and the firm plans capacity to serve demand over the next decade.
Likely market impact
Positive for growth outlook. New peptide capacity is operational ahead of plan, supported by 116 percent revenue growth and an expanding customer pipeline.